Combination chemotherapy for hormone-refractory prostate carcinoma: progress and pitfalls.
Samira
S
Syed
D000726:Androgen Antagonists / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D019008:Drug Resistance, Neoplasm; D004961:Estramustine / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D008297:Male; D017239:Paclitaxel / Q000008:administration & dosage; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome
D000726:Androgen Antagonists; D004961:Estramustine; D005047:Etoposide; D017239:Paclitaxel